rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Amir Nashat

Director and 10% owner

Company insider

Files Form 4 as: Director and 10% owner, CAMP4 Therapeutics; Director, Morphic Holding; Director and 10% owner, Scholar Rock Holding; Director and 10% owner, Syros Pharmaceuticals; Director and 10% owner, Metacrine; Director and 10% owner, Fate Therapeutics; Director and 10% owner, Cartesian Therapeutics; Director, aTyr Pharma.

Every Form 4 they filed

In numbers

Trades disclosed
390
Buys
11
Sells
34
Bought
$40.7M
Sold
$57.2M
Companies
10
Companies where not an officer
10
First trade
14 May 2013
Last trade
10 Jun 2026
Last filed
12 Jun 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
CAMP CAMP4 TherapeuticsDirector, 10% owner · Biotechnology · last 10 Jun 20262 buys · 0 sells
Morphic HoldingDirector · last 16 Aug 20241 buy · 1 sell
SRRK Scholar Rock HoldingDirector, 10% owner · Biotechnology · last 9 May 20242 buys · 0 sells
Syros PharmaceuticalsDirector, 10% owner · last 1 Jun 20221 buy · 0 sells
MetacrineDirector, 10% owner · last 18 May 20221 buy · 0 sells
FATE Fate TherapeuticsDirector, 10% owner · Biotechnology · last 1 Aug 20191 buy · 20 sells
RNAC Cartesian TherapeuticsDirector, 10% owner · Biotechnology · last 14 Jun 20192 buys · 5 sells
ATYR aTyr PharmaDirector · Biotechnology · last 15 May 20180 buys · 0 sells
BIND TherapeuticsDirector · last 9 Jun 20150 buys · 0 sells
ReceptosDirector · last 3 Jun 20141 buy · 8 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
01Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
10 Jun 2026filed 12 Jun 2026CAMP CAMP4 Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—28,000 at $0.00filing
10 Jun 2026filed 12 Jun 2026CAMP CAMP4 Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—28,000 at $0.00filing
11 Sep 2025filed 11 Sep 2025CAMP CAMP4 TherapeuticsBiotechnologySEC FORM 4 Bought$1.9M1,221,721 at $1.53filing
11 Sep 2025filed 11 Sep 2025CAMP CAMP4 TherapeuticsBiotechnologySEC FORM 4 Bought$131K85,468 at $1.53filing
25 Jun 2025filed 27 Jun 2025CAMP CAMP4 Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—9,000 at $0.00filing
15 Oct 2024filed 15 Oct 2024CAMP CAMP4 Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—14,020,475filing
15 Oct 2024filed 15 Oct 2024CAMP CAMP4 Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—980,829filing
15 Oct 2024filed 15 Oct 2024CAMP CAMP4 Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—3,967,234filing
15 Oct 2024filed 15 Oct 2024CAMP CAMP4 Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—277,536filing
15 Oct 2024filed 15 Oct 2024CAMP CAMP4 TherapeuticsBiotechnologySEC FORM 4 Code C—1,250,061filing
15 Oct 2024filed 15 Oct 2024CAMP CAMP4 TherapeuticsBiotechnologySEC FORM 4 Code C—87,448filing
15 Oct 2024filed 15 Oct 2024CAMP CAMP4 TherapeuticsBiotechnologySEC FORM 4 Code C—353,718filing
15 Oct 2024filed 15 Oct 2024CAMP CAMP4 TherapeuticsBiotechnologySEC FORM 4 Code C—24,745filing
15 Oct 2024filed 15 Oct 2024CAMP CAMP4 TherapeuticsBiotechnologySEC FORM 4 Bought$10.0M909,090 at $11.00filing
16 Aug 2024filed 20 Aug 2024Morphic Holdingoption or derivativeSEC FORM 4 Code D—24,000filing
16 Aug 2024filed 20 Aug 2024Morphic Holdingoption or derivativeSEC FORM 4 Code D—12,000filing
16 Aug 2024filed 20 Aug 2024Morphic Holdingoption or derivativeSEC FORM 4 Code D—9,910filing
16 Aug 2024filed 20 Aug 2024Morphic Holdingoption or derivativeSEC FORM 4 Code D—17,550filing
16 Aug 2024filed 20 Aug 2024Morphic Holdingoption or derivativeSEC FORM 4 Code D—12,535filing
16 Aug 2024filed 20 Aug 2024Morphic Holdingoption or derivativeSEC FORM 4 Code D—23,168filing

News

Analyzing Fate Therapeutics (NASDAQ:FATE) & Applied Therapeutics (NASDAQ:APLT)FATE · dailypolitical.com · 19 Oct 2026Scholar Rock Resubmits Marketing Authorisation Application For ApitegromabSRRK · rttnews.com · 8 Oct 2026

0 headlines in the last 90 days name Amir Nashat; 2 articles from the last 14 days about the 4 companies they traded most, at most three about any one of them.

Sectors

Health Care32
Not placed13

Buys in green, sells in red, by the company’s sector.

Related people

Kelly GoldChief Financial Officer · Chief Financial Officer at Camp4 Therapeutics, filing Form 4 there in the last year
Andrew J. SchwabDirector and 10% owner · Director at Camp4 Therapeutics, filing Form 4 there in the last year
Daniel TardiffChief Scientific Officer · Chief Scientific Officer at Camp4 Therapeutics, filing Form 4 there in the last year
5AM Partners VI, LLC10% owner · 10% owner at Camp4 Therapeutics, filing Form 4 there in the last year
Richard A. YoungDirector · Director at Camp4 Therapeutics, filing Form 4 there in the last year
Bahram ValamehrPresident and CEO · Also traded FATE in the last 90 days
Cindy TahlOfficer · Also traded FATE in the last 90 days
Josh Mandel-BrehmChief Executive Officer · Also traded CAMP in the last 90 days